Refractory High Risk Myelodysplastic Syndrome Clinical Trials

6 clinical trials for Refractory High Risk Myelodysplastic Syndrome across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome — RECRUITING · PHASE2
• Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome — RECRUITING · PHASE1
• CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia — RECRUITING · PHASE1
• Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome — COMPLETED · PHASE1
• Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome — COMPLETED · PHASE1
• Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS — COMPLETED · PHASE1

Refine this search